Opioid Induced Constipation (OIC)

Also known as: Opioid-Induced Constipation / Opioid induced constipation / Opioid-induced Constipation (OIC) / Constipation, unspecified / Constipation (& symptom) / Constipation

DrugDrug NameDrug Description
DB01046LubiprostoneLubiprostone is a medication used in the management of idiopathic chronic constipation. It is a bicyclic fatty acid (prostaglandin E1 derivative) which acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).
DB06800MethylnaltrexoneMethylnaltrexone is a pheriphally-acting μ-opioid antagonists that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. FDA approved in 2008.
DB11691NaldemedineNaldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
DB09049NaloxegolNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
DB06480PrucalopridePrucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.[A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
DrugDrug NamePhaseStatusCount
DB09049Naloxegol1Completed1
DB12013Axelopran1 / 2Completed1
DB12013Axelopran2Completed3
DB12464Bevenopran2Completed1
DB08890Linaclotide2Completed1
DB06800Methylnaltrexone2Completed1
DB09049Naloxegol2Completed1
DB06800Methylnaltrexone2 / 3Recruiting1
DB12464Bevenopran3Terminated4
DB06800Methylnaltrexone3Completed1
DB06800Methylnaltrexone3Unknown Status1
DB11691Naldemedine3Completed3
DB09049Naloxegol3Completed4
DB09049Naloxegol3Terminated1
DB06480Prucalopride3Terminated1
DB01079Tegaserod3Terminated2
DB09020Bisacodyl4Completed1
DB11121Chloroxylenol4Completed1
DB06800Methylnaltrexone4Completed2
DB06800Methylnaltrexone4Withdrawn1
DB09049Naloxegol4Completed1
DB01183Naloxone4Unknown Status1
DB00497Oxycodone4Unknown Status1
DB09287Polyethylene glycol4Completed2
DB11365Sennosides4Completed1
DB01046LubiprostoneNot AvailableRecruiting1
DB06800MethylnaltrexoneNot AvailableCompleted1
DB11691NaldemedineNot AvailableRecruiting1
DB09049NaloxegolNot AvailableRecruiting5